{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:19:06Z","timestamp":1793139546912,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1212\/01.con.0000418644.32032.7b","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T18:56:31Z","timestamp":1381517791000},"page":"807-822","source":"Crossref","is-referenced-by-count":33,"title":["Medication-Overuse Headache"],"prefix":"10.1212","volume":"18","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee; Olesen J Bousser M-G Diener H-C et al.. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26 (6): 742\u2013746.","DOI":"10.1111\/j.1468-2982.2006.01172.x"},{"key":"e_1_3_1_4_2","unstructured":"OnabotulinumtoxinA US prescribing information 2011. www.allergan.com\/assets\/pdf\/botox_pi.pdf. Published August 2011. Updated November 2011. Accessed March 6 2012."},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Bigal ME Serrano D Buse D et al.. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48 (8): 1157\u20131168.","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Manack A Buse DC Serrano D et al.. Rates predictors and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76 (8): 711\u2013718.","DOI":"10.1212\/WNL.0b013e31820d8af2"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Munakata J Hazard E Serrano D et al.. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009; 49 (4): 498\u2013508.","DOI":"10.1111\/j.1526-4610.2009.01369.x"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Warner-Schmidt JL Vanover KE Chen EY et al.. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011; 108 (22): 9262\u20139267.","DOI":"10.1073\/pnas.1104836108"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Fumal A Laureys S Di Clemente L et al.. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129 (pt 2): 543\u2013550.","DOI":"10.1093\/brain\/awh691"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Aurora SK Barrodale PM Tipton RL Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache 2007; 47 (7): 996\u20131003; discussion 1004\u20131007.","DOI":"10.1111\/j.1526-4610.2007.00853.x"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Welch KM Nagesh V Aurora SK Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41 (7): 629\u2013637.","DOI":"10.1046\/j.1526-4610.2001.041007629.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Kruit MC Launer LJ Overbosch J et al.. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia 2009; 29 (3): 351\u2013359.","DOI":"10.1111\/j.1468-2982.2008.01723.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Tepper SJ Lowe MJ Beall E et al.. Iron deposition in pain-regulatory nuclei in episodic migraine and chronic daily headache by MRI. Headache 2012; 52 (2): 236\u2013243.","DOI":"10.1111\/j.1526-4610.2011.02056.x"},{"key":"e_1_3_1_27_2","unstructured":"Isler H. Migraine treatment as a cause of chronic migraine. In: Rose FC ed. Advances in migraine research and therapy. New York NY: Raven Press 1982: 159\u2013164."},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Bahra A Walsh M Menon S Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003; 43 (3): 179\u2013190.","DOI":"10.1046\/j.1526-4610.2003.03041.x"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Diener H-C Bussone G Van Oene JC et al.. Topiramate reduces headache days in chronic migraine: a randomized double-blind placebo-controlled study. Cephalalgia 2007; 27 (7): 814\u2013823.","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Silberstein SD Lipton RB Dodick DW et al.. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized double-blind placebo-controlled trial. Headache 2007; 47 (2): 170\u2013180.","DOI":"10.1111\/j.1526-4610.2006.00684.x"},{"key":"e_1_3_1_34_2","unstructured":"Aurora SK Dodick DW Turkel CC et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind randomized placebo-controlled phase of the PREEMPT 1 trial."},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Diener HC Dodick DW Aurora SK et al.; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind randomized placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (7): 804\u2013814.","DOI":"10.1177\/0333102410364677"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Silberstein SD Holland S Freitag F et al.. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17): 1337\u20131345.","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Romero CE Baron JD Knox AP et al.. Barbiturate withdrawal following Internet purchase of Fioricet. Arch Neurol 2004; 61 (7): 1111\u20131112.","DOI":"10.1001\/archneur.61.7.1111"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Diener H-C. How to treat medication-overuse headache: prednisolone or no prednisolone? Neurology 2007; 69 (1): 14\u201315.","DOI":"10.1212\/01.wnl.0000269324.27980.a9"},{"key":"e_1_3_1_42_2","unstructured":"McLean W Boucher EA Brennan M et al.. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association. Can J Clin Pharmacol 2000; 7 (4): 191\u2013197."}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/01.CON.0000418644.32032.7b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:06:51Z","timestamp":1752156411000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000418644.32032.7b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1212\/01.CON.0000418644.32032.7b"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000418644.32032.7b","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}